Stephen P. MacMillan

Stephen P. MacMillan
Born New Jersey
Occupation Chairman, President and Chief Executive Officer of Hologic
Spouse(s) Jennifer MacMillan

Stephen P. MacMillan is the President, Chief Executive Officer, and Director of Hologic, a medical device and diagnostic manufacturer headquartered in Bedford, Massachusetts. He was previously the Chairman of the Board, President, and Chief Executive Officer of Stryker Corporation.Stephen P. MacMillan is the former President and CEO of Stryker Corporation, a global medical device company, and has 24 years of healthcare industry operating experience. He served as Chief Executive Officer of Stryker from January 2005 to February 2012 and served as its President from June 2003 to February 2012. During his tenure at Stryker, MacMillan successfully led the company through a series of key strategic acquisitions, the launch of a number of products within the orthopedic implants and medical instrumentation businesses, and delivered strong operating performance, with revenue growing from $2.8 billion to $8.3 billion, between 2003 and 2011. During his tenure, Stryker delivered stock price appreciation of more than 62%, compared to appreciation of the S&P 500 index of approximately 40%. While MacMillan presided as CEO, Stryker was selected by FORTUNE, over multiple consecutive years, as one of the "World's Most Admired Companies" in the Medical Equipment Industry. Prior to Stryker, MacMillan was a senior executive at Pharmacia Corporation, a global pharmaceutical company, where he oversaw five global businesses with revenue exceeding $2 billion, including one in diagnostics. MacMillan began his career with Procter & Gamble in 1985 and later spent 11 years with Johnson & Johnson in both the U.S. and Europe, and became President of the joint venture between Johnson & Johnson and Merck. MacMillan currently serves on the Board of Directors of Alere Inc. He has previously served on the Boards of Directors of Texas Instruments, the Greater Kalamazoo United Way and AdvaMed, and was a member of the Institute of Medicine's Roundtable on Value & Science-Driven Health Care. In 2010, MacMillan was also appointed by the U.S. Commerce Secretary to a two-year term on the U.S. Manufacturing Council, a group which advised the administration on ideas to create more U.S. manufacturing jobs. He received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School's Advanced Management Program.

Education

MacMillan received a B.A degree in Economics from Davidson College. Where he was Captain of the golf team and is a graduate of Harvard Business School's Advanced Management Program.

Career

On April 1, 2015 the board of Boston Scientific appointed MacMillan to its ranks.

On December 9, 2013, MacMillan was named President and Chief Operating Officer of Hologic, succeeding Jack W. Cumming in this role.[1]

Prior to Hologic, MacMillan served as president and chief executive officer of Stryker from 2005 to 2012 He resigned from Stryker on February 8, 2012.

Prior to joining Stryker, MacMillan was sector vice president, Global Specialty Operations of Pharmacia Corporation. He previously served as president of Johnson & Johnson – Merck Consumer Pharmaceuticals since 1999. He had held numerous other roles at Johnson & Johnson since 1989, including vice president, marketing and professional sales at McNeil Consumer Specialty Pharmaceuticals, and managing director of the U.K. subsidiary of Johnson & Johnson MSD (Merck). He began his career with Procter & Gamble in 1985, where he held various marketing positions.

MacMillan also served on the board of directors of Texas Instruments, Alere, the Advanced Medical Technology Association (AdvaMed), Southwest Michigan First and the Greater Kalamazoo United Way.

Compensation

While CEO of Stryker Corporation in 2008, MacMillan earned a total compensation of $2,118,059, which included a base salary of $1,200,000, and a cash bonus of $617,280.[2]

References

External links

This article is issued from Wikipedia - version of the 9/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.